At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 301 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
R940343 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Doses of Inhaled R940343 in Patients With Mild to Moderate Allergic Asthma
In Brief
A Phase 2 clinical trial evaluating Placebo, R940343 1mg, and 1 other intervention for Asthma. Completed, enrolled 301 participants across 59 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartJul 2012
Primary CompletionJul 2013
TodayJul 2026
First PostedMay 3, 2012
Enrollment StartJul 1, 2012
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.2 years ago
Interventions
Placebodrug
1 puff bid or 2 puffs bid
R940343 1mgdrug
R343 1mg, 1 puff bid
R940343 2mgdrug
R343 2mg, 2 puffs bid